Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis

Table 1

Patient characteristics.

Characteristic	Dose dense docetaxel group ()	Weekly paclitaxel group ()	value
Mean age (yrs)
Standard deviation			0.02
Range	26-69	31-71
Pathology
IDC	42 (95.5)	46 (97.9)	0.335
Other	2 (4.5)	1 (2.1)
T stage
T1 -T2	28 (68.3)	35 (81.4)	0.16
T3 -T4	13 (31.7)	8 (18.6)
N stage
N1	19 (46.3)	24 (53.3)	0.731
N2	14 (34.1)	12 (26.7)
N3	8 (19.5)	9 (20)
Hormone receptors
ER(+)/PR(+)	26 (59.1)	27 (57.4)	0.59
ER(+)/PR(-)	3 (6.8)	7 (14.9)
ER(-)/PR(+)	2 (4.5)	1 (2.1)
ER(-)/PR(-)	13 (29.6)	12 (25.6)
HER2 status
Positive	32 (72.7)	28 (71.8)	0.92
Negative	12 (27.3)	11 (28.2)

Data presented as no. (%) unless otherwise specified.